Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10323560" target="_blank" >RIV/00064165:_____/16:10323560 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10323560
Result on the web
<a href="http://dx.doi.org/10.1212/CPJ.0000000000000227" target="_blank" >http://dx.doi.org/10.1212/CPJ.0000000000000227</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/CPJ.0000000000000227" target="_blank" >10.1212/CPJ.0000000000000227</a>
Alternative languages
Result language
angličtina
Original language name
Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS
Original language description
Methods: The study population initiated IFN-Beta/GA in the MSBase Registry or natalizumab in the Tysabri Observational Program, had >=3 months of on-treatment follow-up, and had active RRMS, defined as >=1 gadolinium-enhancing lesion on cerebral MRI at baseline or >=1 relapse within the 12 months prior to baseline. Baseline demographics and disease characteristics were balanced between propensity-matched groups. Annualized relapse rate (ARR), time to first relapse, treatment persistence, and disability outcomes were compared between matched treatment arms in the total population (n 366/group) and subgroups with higher baseline disease activity. Results: First-line natalizumab was associated with a 68% relative reduction in ARR from a mean (SD) of 0.63 (0.92) on IFN-Beta/GA to 0.20 (0.63) (p [signed-rank] < 0.0001), a 64% reduction in the rate of first relapse (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.28-0.47; p < 0.001), and a 27% reduction in the rate of discontinuation (HR 0.73, 95% CI 0.58-0.93; p 0.01), compared with first-line IFN-Beta/GA therapy. Confirmed disability progression and area under the Expanded Disability Status Scale-time curve analyses were not significant. Similar relapse and treatment persistence results were observed in each of the higher disease activity subgroups. Conclusions: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse and treatment persistence outcomes compared to first-line IFN-Beta/GA. This needs to be balanced against the risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients. Classification of evidence: This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse rates and treatment persistence outcomes compared to first-line IFN-Beta/GA.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neurology: Clinical Practice
ISSN
2163-0402
e-ISSN
—
Volume of the periodical
6
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
102-115
UT code for WoS article
000392602400009
EID of the result in the Scopus database
2-s2.0-84962686361